Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 203

1.

Maximizing the impact of HIV prevention technologies in sub-Saharan Africa.

Ward H, Garnett GP, Mayer KH, Dallabetta GA.

J Int AIDS Soc. 2019 Jul;22 Suppl 4:e25319. doi: 10.1002/jia2.25319. No abstract available.

2.

Reaching and targeting more effectively: the application of market segmentation to improve HIV prevention programmes.

Gomez A, Loar R, Kramer AE, Garnett GP.

J Int AIDS Soc. 2019 Jul;22 Suppl 4:e25318. doi: 10.1002/jia2.25318. No abstract available.

3.

The importance of local epidemic conditions in monitoring progress towards HIV epidemic control in Kenya: a modelling study.

Anderson SJ, Garnett GP, Enstone J, Hallett TB.

J Int AIDS Soc. 2018 Nov;21(11):e25203. doi: 10.1002/jia2.25203.

4.

Cost-Effectiveness of Interventions to Prevent HIV Acquisition.

Garnett GP, Krishnaratne S, Harris KL, Hallett TB, Santos M, Enstone JE, Hensen B, Dallabetta G, Revill P, Gregson SAJ, Hargreaves JR.

In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 7.

5.

Documenting and explaining the HIV decline in east Zimbabwe: the Manicaland General Population Cohort.

Gregson S, Mugurungi O, Eaton J, Takaruza A, Rhead R, Maswera R, Mutsvangwa J, Mayini J, Skovdal M, Schaefer R, Hallett T, Sherr L, Munyati S, Mason P, Campbell C, Garnett GP, Nyamukapa CA.

BMJ Open. 2017 Oct 6;7(10):e015898. doi: 10.1136/bmjopen-2017-015898.

6.

HIV Prevention 2020: a framework for delivery and a call for action.

Dehne KL, Dallabetta G, Wilson D, Garnett GP, Laga M, Benomar E, Fakoya A, Baggaley RC, Nelson LJ, Kasedde S, Bermejo A, Warren M, Benedikt C; Global Prevention Focal Point Group.

Lancet HIV. 2016 Jul;3(7):e323-32. doi: 10.1016/S2352-3018(16)30035-2. Review.

PMID:
27365207
7.

The HIV prevention cascade: integrating theories of epidemiological, behavioural, and social science into programme design and monitoring.

Hargreaves JR, Delany-Moretlwe S, Hallett TB, Johnson S, Kapiga S, Bhattacharjee P, Dallabetta G, Garnett GP.

Lancet HIV. 2016 Jul;3(7):e318-22. doi: 10.1016/S2352-3018(16)30063-7. Review.

PMID:
27365206
8.

Providing a conceptual framework for HIV prevention cascades and assessing feasibility of empirical measurement with data from east Zimbabwe: a case study.

Garnett GP, Hallett TB, Takaruza A, Hargreaves J, Rhead R, Warren M, Nyamukapa C, Gregson S.

Lancet HIV. 2016 Jul;3(7):e297-306. doi: 10.1016/S2352-3018(16)30039-X.

9.

Maximising HIV prevention by balancing the opportunities of today with the promises of tomorrow: a modelling study.

Smith JA, Anderson SJ, Harris KL, McGillen JB, Lee E, Garnett GP, Hallett TB.

Lancet HIV. 2016 Jul;3(7):e289-96. doi: 10.1016/S2352-3018(16)30036-4.

10.

Sexually transmitted infection screening uptake and knowledge of sexually transmitted infection symptoms among female sex workers participating in a community randomised trial in Peru.

Kohler PK, Campos PE, Garcia PJ, Carcamo CP, Buendia C, Hughes JP, Mejia C, Garnett GP, Holmes KK.

Int J STD AIDS. 2016 Apr;27(5):402-10. doi: 10.1177/0956462415584488. Epub 2015 May 4.

11.

Risk pathways for gonorrhea acquisition in sex workers: can we distinguish confounding from an exposure effect using a priori hypotheses?

Gomez GB, Ward H, Garnett GP.

J Infect Dis. 2014 Dec 1;210 Suppl 2:S579-85. doi: 10.1093/infdis/jiu484. Review.

12.

Trends in concurrency, polygyny, and multiple sex partnerships during a decade of declining HIV prevalence in eastern Zimbabwe.

Eaton JW, Takavarasha FR, Schumacher CM, Mugurungi O, Garnett GP, Nyamukapa C, Gregson S.

J Infect Dis. 2014 Dec 1;210 Suppl 2:S562-8. doi: 10.1093/infdis/jiu415.

13.

Heterogeneity in risk of pelvic inflammatory diseases after chlamydia infection: a population-based study in Manitoba, Canada.

Davies B, Ward H, Leung S, Turner KM, Garnett GP, Blanchard JF, Yu BN.

J Infect Dis. 2014 Dec 1;210 Suppl 2:S549-55. doi: 10.1093/infdis/jiu483.

14.

Translational epidemiology: developing and applying theoretical frameworks to improve the control of HIV and other sexually transmitted infections.

Ward H, Gregson S, Watts C, Garnett GP.

J Infect Dis. 2014 Dec 1;210 Suppl 2:S547-8. doi: 10.1093/infdis/jiu559. No abstract available.

15.

The theoretical impact and cost-effectiveness of vaccines that protect against sexually transmitted infections and disease.

Garnett GP.

Vaccine. 2014 Mar 20;32(14):1536-42. doi: 10.1016/j.vaccine.2013.11.007.

PMID:
24606635
16.

Reaching the unreachable: providing STI control services to female sex workers via mobile team outreach.

Campos PE, Buffardi AL, Cárcamo CP, García PJ, Buendia C, Chiappe M, Garnett GP, Xet-Mull AM, Holmes KK.

PLoS One. 2013 Nov 25;8(11):e81041. doi: 10.1371/journal.pone.0081041. eCollection 2013.

17.

Vaccinating women previously exposed to human papillomavirus: a cost-effectiveness analysis of the bivalent vaccine.

Turner HC, Baussano I, Garnett GP.

PLoS One. 2013 Sep 26;8(9):e75552. doi: 10.1371/journal.pone.0075552. eCollection 2013.

18.

Increasing adolescent HIV prevalence in Eastern Zimbabwe--evidence of long-term survivors of mother-to-child transmission?

Eaton JW, Garnett GP, Takavarasha FR, Mason PR, Robertson L, Schumacher CM, Nyamukapa CA, Gregson S.

PLoS One. 2013 Aug 7;8(8):e70447. doi: 10.1371/journal.pone.0070447. eCollection 2013.

19.

Effects of unconditional and conditional cash transfers on child health and development in Zimbabwe: a cluster-randomised trial.

Robertson L, Mushati P, Eaton JW, Dumba L, Mavise G, Makoni J, Schumacher C, Crea T, Monasch R, Sherr L, Garnett GP, Nyamukapa C, Gregson S.

Lancet. 2013 Apr 13;381(9874):1283-92. doi: 10.1016/S0140-6736(12)62168-0. Epub 2013 Feb 27.

20.

Transmission dynamics of the four dengue serotypes in southern Vietnam and the potential impact of vaccination.

Coudeville L, Garnett GP.

PLoS One. 2012;7(12):e51244. doi: 10.1371/journal.pone.0051244. Epub 2012 Dec 10.

21.

Understanding the modes of transmission model of new HIV infection and its use in prevention planning.

Case KK, Ghys PD, Gouws E, Eaton JW, Borquez A, Stover J, Cuchi P, Abu-Raddad LJ, Garnett GP, Hallett TB; HIV Modelling Consortium.

Bull World Health Organ. 2012 Nov 1;90(11):831-838A. doi: 10.2471/BLT.12.102574. Epub 2012 Sep 14.

22.

Developments in the field of HIV estimates: methods, parameters and trends.

Stanecki K, Garnett GP, Ghys PD.

Sex Transm Infect. 2012 Dec;88 Suppl 2:i1-2. doi: 10.1136/sextrans-2012-050885. No abstract available.

23.

Improved STD syndrome management by a network of clinicians and pharmacy workers in Peru: The PREVEN Network.

García PJ, Carcamo CP, Garnett GP, Campos PE, Holmes KK.

PLoS One. 2012;7(10):e47750. doi: 10.1371/journal.pone.0047750. Epub 2012 Oct 17.

24.

The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling study.

Gomez GB, Borquez A, Caceres CF, Segura ER, Grant RM, Garnett GP, Hallett TB.

PLoS Med. 2012;9(10):e1001323. doi: 10.1371/journal.pmed.1001323. Epub 2012 Oct 9.

25.

Patterns of uptake of HIV testing in sub-Saharan Africa in the pre-treatment era.

Cremin I, Cauchemez S, Garnett GP, Gregson S.

Trop Med Int Health. 2012 Aug;17(8):e26-37. doi: 10.1111/j.1365-3156.2011.02937.x.

26.

Prevalences of sexually transmitted infections in young adults and female sex workers in Peru: a national population-based survey.

Cárcamo CP, Campos PE, García PJ, Hughes JP, Garnett GP, Holmes KK; Peru PREVEN study team.

Lancet Infect Dis. 2012 Oct;12(10):765-73. doi: 10.1016/S1473-3099(12)70144-5. Epub 2012 Aug 8.

27.

Could better tolerated HIV drug regimens improve patient outcome?

Smit M, Smit C, Cremin I, Garnett GP, Hallett T, de Wolf F.

AIDS. 2012 Sep 24;26(15):1953-9.

28.

Prevention of sexually transmitted infections in urban communities (Peru PREVEN): a multicomponent community-randomised controlled trial.

García PJ, Holmes KK, Cárcamo CP, Garnett GP, Hughes JP, Campos PE, Whittington WL; Peru PREVEN Study Team.

Lancet. 2012 Mar 24;379(9821):1120-8. doi: 10.1016/S0140-6736(11)61846-1. Epub 2012 Feb 15. Erratum in: Lancet. 2012 Mar 24;379(9821):1102.

29.

Sex with stitches: assessing the resumption of sexual activity during the postcircumcision wound-healing period.

Hewett PC, Hallett TB, Mensch BS, Dzekedzeke K, Zimba-Tembo S, Garnett GP, Todd PE.

AIDS. 2012 Mar 27;26(6):749-56. doi: 10.1097/QAD.0b013e32835097ff.

PMID:
22269970
30.

The clinical interpretation of viral blips in HIV patients receiving antiviral treatment: are we ready to infer poor adherence?

Fung IC, Gambhir M, van Sighem A, de Wolf F, Garnett GP.

J Acquir Immune Defic Syndr. 2012 May 1;60(1):5-11. doi: 10.1097/QAI.0b013e3182487a20.

PMID:
22267019
31.

Treatment as prevention: translating efficacy trial results to population effectiveness.

Garnett GP, Becker S, Bertozzi S.

Curr Opin HIV AIDS. 2012 Mar;7(2):157-63. doi: 10.1097/COH.0b013e3283504ab7. Review.

PMID:
22258503
32.

Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study.

Eisingerich AB, Wheelock A, Gomez GB, Garnett GP, Dybul MR, Piot PK.

PLoS One. 2012;7(1):e28238. doi: 10.1371/journal.pone.0028238. Epub 2012 Jan 11.

33.

Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study.

Hallett TB, Baeten JM, Heffron R, Barnabas R, de Bruyn G, Cremin Í, Delany S, Garnett GP, Gray G, Johnson L, McIntyre J, Rees H, Celum C.

PLoS Med. 2011 Nov;8(11):e1001123. doi: 10.1371/journal.pmed.1001123. Epub 2011 Nov 15.

34.

Could we, should we? Yes.

Fox J, White PJ, Weber J, Garnett GP, Ward H, Fidler S.

AIDS. 2011 Sep 10;25(14):1801. doi: 10.1097/QAD.0b013e32834a1cbb. No abstract available.

PMID:
21876391
35.

Effect of concurrent sexual partnerships on rate of new HIV infections in a high-prevalence, rural South African population: a cohort study.

Tanser F, Bärnighausen T, Hund L, Garnett GP, McGrath N, Newell ML.

Lancet. 2011 Jul 16;378(9787):247-55. doi: 10.1016/S0140-6736(11)60779-4.

36.

Estimating the resources required in the roll-out of universal access to antiretroviral treatment in Zimbabwe.

Hallett TB, Gregson S, Dube S, Mapfeka ES, Mugurungi O, Garnett GP.

Sex Transm Infect. 2011 Dec;87(7):621-8. doi: 10.1136/sti.2010.046557. Epub 2011 Jun 2.

37.

Monitoring trends in HIV prevalence among young people, aged 15 to 24 years, in Manicaland, Zimbabwe.

Marsh KA, Nyamukapa CA, Donnelly CA, Garcia-Calleja JM, Mushati P, Garnett GP, Mpandaguta E, Grassly NC, Gregson S.

J Int AIDS Soc. 2011 May 24;14:27. doi: 10.1186/1758-2652-14-27.

38.

Quantifying sexual exposure to HIV within an HIV-serodiscordant relationship: development of an algorithm.

Fox J, White PJ, Weber J, Garnett GP, Ward H, Fidler S.

AIDS. 2011 May 15;25(8):1065-82. doi: 10.1097/QAD.0b013e328344fe4a. Review.

PMID:
21537113
39.

Introduction to recent developments in HIV epidemic modeling.

Wilson DP, Garnett GP.

Curr Opin HIV AIDS. 2011 Mar;6(2):91-3. doi: 10.1097/COH.0b013e328343c02e. No abstract available.

PMID:
21505381
40.

Mathematical models in the evaluation of health programmes.

Garnett GP, Cousens S, Hallett TB, Steketee R, Walker N.

Lancet. 2011 Aug 6;378(9790):515-25. doi: 10.1016/S0140-6736(10)61505-X. Epub 2011 Apr 8. Review.

PMID:
21481448
41.

HPV-16 infection and cervical cancer: modeling the influence of duration of infection and precancerous lesions.

Baussano I, Ronco G, Segnan N, French K, Vineis P, Garnett GP.

Epidemics. 2010 Mar;2(1):21-8. doi: 10.1016/j.epidem.2010.02.002. Epub 2010 Feb 10.

PMID:
21352773
42.

U.K. immigrant screening is inversely related to regional tuberculosis burden.

Pareek M, Abubakar I, White PJ, Garnett GP, Lalvani A.

Thorax. 2011 Nov;66(11):1010. doi: 10.1136/thx.2010.152280. Epub 2011 Feb 16. No abstract available.

PMID:
21325664
43.

Did national HIV prevention programs contribute to HIV decline in Eastern Zimbabwe? Evidence from a prospective community survey.

Gregson S, Nyamukapa C, Schumacher C, Mugurungi O, Benedikt C, Mushati P, Campbell C, Garnett GP.

Sex Transm Dis. 2011 Jun;38(6):475-82. doi: 10.1097/OLQ.0b013e3182080877.

44.

Condom use by female sex workers and their clients in Mexico: who decides and does it matter?

Bórquez A, Hallett TB, Gomez GB, Garnett GP.

Sex Transm Infect. 2011 Apr;87(3):254-6. doi: 10.1136/sti.2010.048736. Epub 2011 Jan 26.

45.

Promising control of genital warts: but is elimination possible?

Lacey CJ, Garnett GP.

Lancet Infect Dis. 2011 Jan;11(1):4-6. doi: 10.1016/S1473-3099(10)70297-8. No abstract available.

PMID:
21183139
46.

Tuberculosis screening of migrants to low-burden nations: insights from evaluation of UK practice.

Pareek M, Abubakar I, White PJ, Garnett GP, Lalvani A.

Eur Respir J. 2011 May;37(5):1175-82. doi: 10.1183/09031936.00105810. Epub 2010 Nov 11.

47.

Antiretroviral treatment is a behavioural intervention: but why?

Gregson S, Garnett GP.

AIDS. 2010 Nov 13;24(17):2739-40. doi: 10.1097/QAD.0b013e32833f6ea2. No abstract available.

48.

Measuring and correcting biased child mortality statistics in countries with generalized epidemics of HIV infection.

Hallett TB, Gregson S, Kurwa F, Garnett GP, Dube S, Chawira G, Mason PR, Nyamukapa CA.

Bull World Health Organ. 2010 Oct 1;88(10):761-8. doi: 10.2471/BLT.09.071779. Epub 2010 Apr 7.

49.

Concurrent sexual partnerships and primary HIV infection: a critical interaction.

Eaton JW, Hallett TB, Garnett GP.

AIDS Behav. 2011 May;15(4):687-92. doi: 10.1007/s10461-010-9787-8.

50.

Studying complex interactions among determinants of healthcare-seeking behaviours: self-medication for sexually transmitted infection symptoms in female sex workers.

Gomez GB, Campos PE, Buendia C, Carcamo CP, Garcia PJ, Segura P, Whittington WL, Hughes JP, Ward H, Garnett GP, Holmes KK.

Sex Transm Infect. 2010 Aug;86(4):285-91. doi: 10.1136/sti.2009.036806.

PMID:
20660592

Supplemental Content

Loading ...
Support Center